Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Braveheart Bio Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Braveheart Bio Inc. market cap is $2.11B.
What is the 52-week high for Braveheart Bio Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Braveheart Bio Inc. 52 week high is $31.56 as of August 07, 2026.
What is the 52-week low for Braveheart Bio Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Braveheart Bio Inc. 52 week low is $18.00 as of August 07, 2026.
What is Braveheart Bio Inc. stock price today?
Braveheart Bio Inc. stock price today is $29.80.
What was Braveheart Bio Inc. stock price yesterday?
Braveheart Bio Inc. stock price yesterday was $18.00.
What is the Price-to-Book ratio of Braveheart Bio Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Braveheart Bio Inc. P/B ratio is -26.858.
What is the 50-day moving average of Braveheart Bio Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Braveheart Bio Inc. 50-day moving average is $23.90.